National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix T: Additional Sources of Advice to the Committee." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
451
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Walter R.Dowdle, The Centers for Disease Control, Atlanta, Ga.

Gordon R.Dreesman, Baylor College of Medicine, Houston, Tex.

David J.Drutz, University of Texas Health Sciences Center, San Antonio.

Robert Edelman, National Institutes of Health, Bethesda, Md.

Paul Eggers, Health Care Financing Administration, Baltimore, Md.

Roger W.Evans, Battelle Human Affairs Research Centers, Seattle, Wash.

Stanley Falkow, Stanford University, Calif.

Patricia Ferrieri, University of Minnesota, Minneapolis.

Samuel B.Formal, Walter Reed Army Medical Center, Wash., D.C.

Hjordis M.Foy, University of Washington, Seattle.

Donald P.Francis, The Centers for Disease Control, Atlanta, Ga.

Carl E.Frasch, Food and Drug Administration, Bethesda, Md.

Vincent A.Fulginiti, University of Arizona College of Medicine, Tuscon.

Robert J.Gerety, Food and Drug Administration, Bethesda, Md.

Anne A.Gershon, New York University Medical School, N.Y.

Janet R.Gilsdorf, C.S.Mott Children’s Hospital, Ann Arbor, Mich.

W.Paul Glezen, Baylor College of Medicine, Houston, Tex.

Sherwood L.Gorbach, Tufts University, Boston, Mass.

Lance K.Gordon, Connaught Research Institute, Ontario, Canada.

Samuel P.Gotoff, University of Chicago, 111.

Emil C.Gotschlich, The Rockefeller University, New York, N.Y.

Dan M.Granoff, Washington University in St. Louis, Mo.

Darrel D.Gwinn, National Institutes of Health, Bethesda, Md.

James Barry Hanshaw, University of Massachusetts Medical School, Worcester.

M.Carolyn Hardegree, Food and Drug Administration, Bethesda, Md.

George R.Healy, The Centers for Disease Control, Atlanta, Ga.

James C.Hill, National Institutes of Health, Bethesda, Md.

King K.Holmes, Seattle Public Health Hospital, Wash.

Frederick B.Hollinger, Baylor College of Medicine, Houston, Tex.

Eugene S.Hurwitz, The Centers for Disease Control, Atlanta, Ga.

Robert E.Johnson, The Centers for Disease Control, Atlanta, Ga.

Albert Z.Kapikian, National Institutes of Health, Bethesda, Md.

Karl Kappus, The Centers for Disease Control, Atlanta, Ga.

Stanislav V.Kasl, Yale University School of Medicine, New Haven, Conn.

Dennis L.Kasper, Harvard Medical School, Boston, Mass.

Edward H.Kass, Harvard Medical School, Boston, Mass.

Alan P.Kendal, The Centers for Disease Control, Atlanta, Ga.

Edwin D.Kilbourne, Mount Sinai Medical Center, New York, N.Y.

David L.Klein, National institutes of Health, Bethesda, Md.

Jerome O.Klein, Boston City Hospital, Mass.

William J.Klish, Baylor College of Medicine, Boston, Tex.

Saul Krugman, New York University School of Medicine, N.Y.

John R.La Montagne, National Institutes of Health, Bethesda, Md.

Martha L.Lepow, Albany Medical College, N.Y.

Richard A.Lerner, Scripps Clinic and Research Foundation, La Jolla, Calif.

Sol Levine, Boston University, Mass.

Charles R.Manclark, Food and Drug Administration, Bethesda, Md.

Page
451
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)